CD38 and Miyoshi myopathy: Anti-CD38 MoAbs exert their MM cytotoxicity through different mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), the modulation of CD38 ectoenzyme activity, and direct effects [4].